Surgery After Induction Therapy Did Not Improve Survival in RENAISSANCE
The central question in oligometastatic gastro-oesophageal adenocarcinoma is no longer whether systemic therapy matters most. It does. The sharper issue is whether surgery adds enough on top of disease control achieved with induction treatment to justify the burden of an operation in patients whose disease has already shown it can be contained, at least temporarily, by chemotherapy.
A commentary on the August 2026 review by Zhu and colleagues argues that the randomized evidence still falls short of validating surgical consolidation as a routine strategy in this setting. The concern is not theoretical. It comes directly from the phase III RENAISSANCE trial, which used a response-based design and still failed to deliver a statistically significant overall survival benefit for the surgery arm.
One result stands out immediately: the trial did not meet its primary endpoint.
Response-Selected Patients Still Did Not Gain a Survival Advantage
RENAISSANCE, also known as IKF-575/AIO-FLOT5, enrolled patients with limited-metastatic adenocarcinoma of the stomach or esophagogastric junction who had no disease progression after four cycles of FLOT chemotherapy. Those patients were then randomized to surgery followed by additional FLOT or to continued systemic therapy alone. Randomization was stratified by complete or partial response versus stable disease, so the study already embedded a biologic filter: only patients who had at least disease control on induction treatment could enter the comparison.
Even with that preselection, the intention-to-treat population of 139 patients showed no overall survival advantage for surgery. The hazard ratio was 1.04, with a 95% confidence interval of 0.69 to 1.56 and a P value of 0.86. In practical terms, the trial did not demonstrate that adding resection improved survival over continued systemic treatment.
The median overall survival values have also been presented in a way that matters. In the review, the medians are listed as 23.6 months versus 18.5 months in the order surgery versus systemic therapy. Yet the 2024 ASCO Annual Meeting presentation reported the reverse: 18.5 months with surgery and 23.6 months with systemic therapy alone. The sequence is not a semantic detail. It changes the apparent direction of the result. The trial itself did not support a numerical survival edge for surgery.
Postoperative Risk and Treatment Disruption Shaped the Net Effect
The biology of oligometastatic disease does not erase the cost of major surgery. In RENAISSANCE, 90-day mortality after resection was 8%. That rate is difficult to ignore when the operation is being offered to patients who have already received intensive induction therapy and still need more systemic treatment to control micrometastatic disease.
Chemotherapy delivery after randomization also differed sharply between the groups. At least four further cycles of chemotherapy were administered to 42% of patients assigned to surgery, compared with 71% of those assigned to systemic therapy alone. In other words, the surgical pathway did not merely add a local treatment; it also appears to have reduced the likelihood that patients received the planned postoperative systemic therapy that remains central to disease control.
That pattern is clinically important because postoperative morbidity, recovery time, and early mortality can erode the very benefit surgeons hope to secure. If a patient survives the operation but cannot resume effective systemic therapy, the therapeutic balance shifts quickly. The issue is not whether surgery can remove visible disease. It is whether removal of visible disease translates into longer life once the price of the intervention is counted in missed chemotherapy, complications, and death within 90 days.
Stable Disease Is Not the Same as a Favorable Biology Signal
The trial design also raises a subtler problem: “no progression” is not the same as a robust response. Patients with stable disease were eligible alongside those with complete or partial response. That matters because stable disease may simply mean temporary restraint under treatment, not a tumor biology that is likely to be converted into durable benefit by resection.
The selection rules in RENAISSANCE were broader than the newer OMEC-4 criteria for oligometastatic gastro-oesophageal cancer. Those European definitions are narrower, and the trial commentary suggests that future studies should focus even more tightly on patients with retroperitoneal nodal metastases only. Within the current trial, that subgroup comprised 20% of the intention-to-treat cohort and had a reported median overall survival of 30 months versus 17 months, despite increased early mortality. The signal is intriguing, but it is still subgroup-level evidence, not a basis for routine practice.
This is where the randomized data and the surgical enthusiasm part company. A patient can respond to induction FLOT and still not derive a net survival gain from resection. Response selection reduces risk, but it does not prove that surgery improves the outcome it is meant to improve.
What the Trial Actually Supports in Daily Practice
The strongest reading of the evidence is narrower than a broad endorsement of sequential surgery. RENAISSANCE supports the idea that systemic therapy should remain the backbone of treatment for patients with limited-metastatic gastro-oesophageal adenocarcinoma. It also shows that a strategy of surgery after induction treatment is not automatically superior, even when patients are preselected for disease control.
For now, the randomized evidence applies to patients already chosen by response to induction therapy, not to a general metastatic population and not yet to a clearly defined surgical-benefit subgroup. The study does not validate response-based selection as a reliable method for identifying patients who will live longer because they had surgery.
That leaves a practical gap. The next step is not simply more surgery or less surgery, but tighter selection criteria and more precise trial design. If future protocols concentrate on the subgroup with retroperitoneal nodal metastases and similar anatomic constraints, they may better isolate whether resection can help a very specific oligometastatic phenotype. Until then, the combination of 8% 90-day mortality, reduced postoperative chemotherapy delivery, and a neutral overall survival result keeps the bar for surgical consolidation high.